Clinical Trial: A Long-term Trial of EB-1020 in Adult Patients With ADHD

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926829) titled 'A Long-term Trial of EB-1020 in Adult Patients With ADHD' on April 11.

Brief Summary: The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Attention Deficit Hyperactivity Disorder (ADHD)

Intervention: DRUG: EB-1020 (Centanafadine) 164.4 mg

164.4 mg, capsule, oral, once daily, for 52 weeks

DRUG: EB-1020 (Centanafadine) 328.8 mg

328.8 mg, capsule, oral, once daily, for 52 weeks

Recruitment Status: R...